Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2023 Jul 24;109(3):624-625.
doi: 10.4269/ajtmh.23-0177. Print 2023 Sep 6.

Case Report: Extensive Facial Cutaneous Leishmaniasis in a Neonate

Affiliations
Case Reports

Case Report: Extensive Facial Cutaneous Leishmaniasis in a Neonate

Sapir Itzhaki Gabay et al. Am J Trop Med Hyg. .

Abstract

Cutaneous leishmaniasis (CL) is a skin infection caused by various species of the Leishmania parasite and is spread by the bite of an infected female sandfly. In southern Israel, CL caused by Leishmania major is endemic. Cutaneous leishmaniasis is considered a self-limiting disease, characterized by progressive, long-lasting nodulo-ulcerative skin lesions, which usually resolve in several months to years, and leads to scarring, cosmetic disfigurement, and future stigmatization. Although CL is a common disease among children, reports of CL in children younger than 1 year are rare. We present a case of extensive facial CL in an infant whose initial lesions appeared only 25 days after birth. The patient was treated with intravenous liposomal amphotericin B. Two months later, marked improvement was seen, with complete resolution of the inflammation and atrophic scar formation. To our knowledge, this is the earliest age of CL published to date.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Large (2–7 cm), ulcerative, thick-scaled nodules located on the scalp, temple, and eyelids of an 11-week-old female.
Figure 2.
Figure 2.
Complete resolution of the inflammation (induration, crust, and erythema) and atrophic scar formation 2 months after treatment with intravenous liposomal amphotericin B.

References

    1. Horev A, Sagi O, Zur E, Ben-Shimol S, 2023. Topical liposomal amphotericin B gel treatment for cutaneous leishmaniasis caused by Leishmania major: a double-blind, randomized, placebo-controlled, pilot study. Int J Dermatol 62: 40–47. - PubMed
    1. Noyman Y, Levi A, Ben Amitai D, Reiss-Huss S, Sabbah F, Hodak E, Mimouni T, Friedland R, 2022. Treating pediatric cutaneous Leishmania tropica with systemic liposomal amphotericin B: a retrospective, single-center study. Dermatol Ther (Heidelb) 35: e15185. - PubMed
    1. Erat T, An I, 2022. Treatment of pediatric cutaneous leishmaniasis with liposomal amphotericin B. Dermatol Ther (Heidelb) 35: e15706. - PubMed
    1. Hussein NR, Naqid IA, Salih HM, 2020. The efficacy and safety of intralesional sodium stibogluconate for the treatment of cutaneous leishmaniasis in children under the age of two years. Mediterr J Hematol Infect Dis 12: e2020027. - PMC - PubMed
    1. Agrawal S, Khandelwal K, Bumb RA, Oghumu S, Salotra P, Satoskar AR, 2014. Pediatric cutaneous leishmaniasis in an endemic region in India. Am J Trop Med Hyg 91: 901–904. - PMC - PubMed

Publication types

Substances

LinkOut - more resources